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18 Oral Presentationsas a source of Adv andCMVantigens. CB-derived dendritic cells were
transduced with the Ad5f35pp65 vector to stimulate virus-specific
CTL followed by stimulation with autologous CB-derived lympho-
blastoid cells (LCL) transducedwith the samevector.After3weeks ex-
pansion, 9 CTL lines contained a mean of 83% (range 64–94%)
CD81 and 27% (range 12–40%) CD41 T-cells. Flow cytometric
analysis of memory markers revealed a predominance of CD45RA-
CD62L- T-cells (69618%; range 25–93) with a smaller population
of CD45RA- CD62L1 T-cells (1065%; range 1–23). Evaluable
CB CTL lines showed specific cytolytic activity in 51Cr release assays
against CMV and Adv targets. IFNg ELISPOT assays on CTL lines
demonstrated a mean of 209 (range 45–694) and 74 (range 0–188)
spot-forming cells/1  105 T-cells following incubation with CMV-
pp65 and Adv-hexon/penton peptides respectively. No significant re-
sponse to irrelevant peptides was demonstrated. The expanded CB
CTL had a broad Vb repertoire and were specific for multiple viral
epitopes. In addition, the virus-specific T cells were shown to be ex-
panded only from T-cells with a naive phenotype (CD45RA1/
CCR71). These results demonstrate that, despite the generally naive
nature of CB lymphocytes, bi-virus-specific responses can be ex-
panded in vitro andcouldpotentially beused clinically inCBTpatients
who develop infectious complications prior to immune reconstitution.41
THE ‘‘MARROWMINER’’, A NOVEL, MINIMALLY INVASIVE DEVICE FOR
THE HARVEST OF BONE MARROW: RESULTS FROM THE MARVELOUS
TRIAL DEMONSTRATE SAFETY, EFFICACY AND IMPROVED STEM CELL
YIELDS COMPARED TO STANDARD MARROW HARVEST METHOD
Kraft, D.1, Crocker, M.2, Ramella, O.3, Ghazarossian, V.2, Carrasco
Yalan, A.3 1Stanford University, Stanford, CA; 2StemCor Systems,
Menlo Park, CA; 3Sangre de Cordon SA de CV, Guadalajara, Mexico
Introduction: Bone marrow (BM) is the traditional graft source in
hematopoietic stem cell transplantation. An increasing body of work
suggests thatuseofBMgraftsmayshow long-termadvantagesovermo-
bilized PBSC in some alloegeneic settings, resulting in less cGVHD,
morbidity and improved survival. Traditional O.R. based BM harvest
methods are crude, labor and resource intensive, generally requiring
100–2001 serial small volume needle aspirates, and result in grafts
highly diluted by peripheral blood. Improved BM harvest methods
are needed. The ‘‘MarrowMiner’’ (MM), is a novel, FDA cleared and
CE-Marked device developed for the minimally invasive harvest of
BM to enable the rapid, convenient, outpatient harvest of large quanti-
ties of BM via a single marrow entry site, under local anesthesia.
Methods:TheMARVELOUS (MARrowMinerVErsus standard
ILeac bOne marrow pUncture and aSpiration) trial was designed to
compare harvest of the MM with standard serial-puncture needle
harvest in the same patient. 21 patients undergoing autologous mar-
row derived cell therapy were enrolled, and had BM harvested under
local anesthesia from their anterior (10) or posterior (11) ileac by the
MM, followed by serial marrow aspirates with standard 6-hole
harvest needles from the opposite hip. Cell viability, counts,
CD341, ALDH1, T cell, and MSC populations were compared.
Results: The MM successfully harvested large volumes (up to
300ml) of marrow under local anesthesia without any complications.Average intrapatient ratio of cell counts from marrow ob-
















1.98 1.22 0.78 7.96 3.56
*Results from initial 10 of 21 patients with full flow cytometry data avail-
able at time of submission.MM harvest samples had a greater average TNC count / ml
compared to standard marrow harvest in the same patient (1.98
greater TNC (0.87–3.3 6 p\.05). Viability was equivalent at
(.99%). In addition to higher TNC/ml, higher levels (mean 3.56
fold) of % ALDH1, CD341, phenotypic MSC (7 fold) and CFU
were obtained by MM while % CD31 was lower.
Conclusions: The novel MarrowMiner system demonstrated
safety and efficacy in clinical use, while harvesting more CD341
cells per ml via single iliac entry compared to standard harvest
methods. This suggests the MM may enable improved clinical har-
vests in a more rapid and minimally invasive manner, improving
donor safety and convenience while obtaining a richer marrow prod-
uct, requiring less total volume and with less peripheral blood con-
tamination. Such a system, facilitating convenient, on demand
stem cell collection and improved safety and convenience for the do-
nor may have significant application for BMT and other marrow
based cell therapies.42
IN UTERO GENE AND CELL THERAPY FOR CONGENITAL DISEAASES
Porta, F.1, Lorenzi, L.1, Bolda, F.1, Bosi, A.1, Gaspar, H.B.2,
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In utero stem cells transplantation (IUSCT) presents immunolog-
ical and therapeutic potentials advantages over postnatal stem cells
transplantation (SCT).The peculiar, immunological status of the fe-
tus allows donor-specific tolerance and can eliminate the require-
ment of pharmacological immunosuppression. Furthermore
IUSCT potentially prevents clinical manifestations that can start at
this stage of development and, indeed, the small size of the foetus al-
lows a much higher relative doses of stem cells, favouring successful
engraftment. Mesenchymal stem cells (MSCs) are multipotent stem
cells able to differentiate into diverse lineages, including osteocytes,
chondrocytes, adipocytes. MSCs have a peculiar homing-capacity,
when injected in animal models, colonizing irradiated mesoderm-
derived tissues, ischemic myocardium, liver and brain.On the ratio-
nal of their trafficking capacity to injured tissues, clinical trials have
been started with the employment of MSCs in the treatment of met-
abolic diseases like Hurler syndrome and metachromatic leukodys-
trophy, or Osteogenesis Imperfecta (OI). Our centre performed
seven in utero transplants in foetuses affected by SCID and Osteo-
genesis Imperfecta with improvement of clinical presentation in
most cases and low procedure related morbility. SCID fetuses have
been transplanted with haematopoietic CD341 stem cells, in three
casesMSCwere coinjected (2 OI;1 SCID).With the aim of realizing
a prenatal gene therapy protocol, our group has successfully isolated,
expanded and characterized human multi-potent MSCs from 11
samples of second-trimester amniotic fluid. These cells result to be
expandable in specific conditions and to express mesenchymal
markers, above all between te 3rd and the 4th week of colture.Telo-
merase activity and telomers length have been evaluated demonstrat-
ing an absent spontaneous transformation tendency. Transduction
efficacy of Amniotic Fluid Mesenchymal Stem Cells (AFMSC) has
been assessed using a SIN HIV-1–based lentiviral vector. This vec-
tor encloses SFFV-U3promoter and eGFP.We found a transduction
efficiency of 60%. We suggest that AFMSCs, with their ready
expandability, ability to differentiate into multiple lineages and
high transduction efficiency, may be good target for neonatal regen-
erative surgery and for in utero gene therapy for diseases candidate
(i.e.x-SCID, CGD, WAS,ADA- SCID).43
THE EFFECT OF INHIBITORY KILLER-CELL IG-LIKE RECEPTOR(IKIR)
MATCHING IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION(HCT)
Senitzer, D., Sun, J.Y., Gaidulis, L., Oki, A., Dagis, A., Palmer, J.,
Forman, S.J. City of Hope National Medical Center, Duarte, CA; City
of Hope National Medical Center, Duarte, CA
Successful treatment of hematological malignancy by HCT is
complicated by the intensity of alloimmune response; too
strong—GVHD, or too weak—relapse. Natural Killer (NK) cell
Oral Presentations 19activity regulated by Killer Immunoglobulin Receptor (KIR) genes
may tip the balance towards either detrimental or beneficial out-
comes. Both recipients and donors of 605 first allogeneic non-T de-
pleted transplants were retrospectively KIR genotyped. In the non-
HLA identical transplants, 92 inhibitory KIR ligand (iKIRL) mis-
matched cases displayed the worst five-year overall survival (OS,
20%) perhaps due to higher non-relapse mortality. In contrast,
75 transplants with only an HLA class-I antigen (Ag) incompatibil-
ity, but without an iKIRL incompatibility had significantly better
OS (41%, p\0.001), which was similar to that (39%) of the Class
I allele mismatched transplants, suggesting that incompatible
iKIRLs exacerbated the effect of HLA Class I mismatches. In the
HLA identical cases, the presence of both patient and donor
2DL/S2 resulted in a better OS (72% vs 58%, p\0.01) due to
less relapse. Interestingly, the impact was concentrated in HLA-
Cw iKIRL group 1 homozygotes. The absence of 2DL/S2 in the re-
cipients decreased OS by 20% (72% vs 52%, p\0.001). The effect
was not observed in the 10/10 (HLA-A, B, C, DRB1, DQB1)
matched transplant cases, suggesting that, NK cell activity in
HCT recipients, may be beneficial when the alloimmune response
is less stimulated. Our study reflects the diversified role of NK cells
inHCT, and suggests that KIR genotypingmay be useful in clinical
practice.IMMUNE RECONSTITUTION
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MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY TO PREVENT OR
TREAT INFECTIONS OF STEM CELL TRANSPLANT RECIPIENTS
Gerdemann, U.1, Christin, A.1, Fujita, Y.1, Vera, J.F.1, Ramos, C.A.1,
Dilloo, D.2, Brenner, M.K.1, Heslop, H.E.1, Rooney, C.M.1,
Leen, A.M.1 1Center for Cell and Gene Therapy, Baylor College of Med-
icine, Methodist Hospital and Texas Children’s Hospital, Houston, TX;
2Clinic for Pediatric Oncology, Heinrich Heine University of Duesseldorf,
Duesseldorf, Germany
Viral infections cause morbidity and mortality in allogeneic
HSCT recipients. To treat the underlying problem, namely lack
of antigen-specific T cells, we and others have successfully gener-
ated and infused adoptive T-cell lines specific for EBV, CMV and
Adenovirus. We have shown that as few as 2  105/kg trivirus-
specific cytotoxic T lymphocytes (CTL) proliferated by several
logs post-infusion and appeared to protect the recipients against
all three viruses. Despite the encouraging clinical results, broader
implementation of the approach is limited by (i) the usage of infec-
tious virus material (EBV/Adv) and (ii) the prolonged culture (3
months for EBV-LCL production and CTL stimulation). Finally,
(iii) ‘‘antigenic competition’’ between multiple viral antigens
limits the extension to additional viruses. To overcome these
limitations we have developed an approach to rapidly produce
multivirus-specific CTL without using adenoviral vectors or
EBV-LCL. Using nucleofection we consistently detected GFP
transgene expression of 39% of transfected DCs, without ad-
versely affecting cell viability or DC maturation status. Coculture
of p-Shuttle-pp65-GFP-transfected DCs with PBMCs from
CMV seropositive individuals reactivated CMV-specific T-cells,
which were detectable 9 days after stimulation, at higher frequen-
cies (as measured by g-IFNELIspot and Pentamer analysis (HLA-
A2, NLV)) than lines generated using our standard protocol with
Ad5f35pp65-transduced DCs as APCs. Importantly, this protocol
could also be used to reactivate T cells against multiple viruses.
Using a panel of p-Shuttle plasmids encoding LMP2 and
BZLF1 (EBV), Large T (BK), and Hexon and Penton (Adv), we
amplified CTLs from seropositive donors specific for the different
viruses. Furthermore, we demonstrated that by pooling trans-
fected DCs prior to PBMC stimulation, we could reproducibly
generate multivirus-specific CTL lines, specific for all the stimu-
lating antigens, without observing antigenic competition. To
shorten the CTL production process, we established the selection
of highly virus-specific T cells by IFN-g capture 24 hours after
DC stimulation. In summary, we have established two GMP-ap-
plicable protocols for the rapid generation (\10 days) of CTL
without using infectious material. In 10 days we can generatemono- or multivirus -specific CTL lines for prophylactic applica-
tion. By performing IFN-g selection we can rapidly generate
virus-specific CTLs for treatment of acute infection.45
DONOR LYMPHOCYTE INFUSIONS DEPLETED OF ALLOREACTIVE T CELLS
DECREASE INFECTIONS WITHOUT CAUSING GVHD AFTER HAPLOTYPE
MISMATCHED MYELOABLATIVE STEM CELL TRANSPLANTATION
Roy, D.-C.1, Cohen, S.1, Busque, L.1, Fish, D.1, Kiss, T.1, Lachance, S.1,
Sauvageau, G.1, Rovers, J.2, Roy, J.1 1Hopital Maisonneuve-Rosemont,
Montreal, QC, Canada; 2Kiadis Pharma, Amsterdam, Netherlands
The ability to accelerate immune reconstitution following
haplo-mismatched stem cell transplantion (SCT) would limit in-
fections and disease relapse, and provide a unique opportunity to
transplant the large number of patients who cannot find an HLA-
matched donor. We present results of a Phase I clinical trial of
haplo-mismatched allogeneic SCT supplemented with a donor
lymphocyte infusion (DLI) photodynamically depleted of host-re-
active T cells using dibromorhodamine as photosensitizer and
visible light illumination (512 nm) (ATIR-PDT, Kiadis Pharma).
Nineteen patients (11 M, 8 F) with high-risk hematologic malig-
nancies (mostly refractory or relapsed acute myeloid leukemia
(10) and myelodysplastic syndromes (4)) entered the trial. Median
age at SCT was 54 years (range: 19–62). Increasing doses of
PDT-treated donor cells (1  104 to 5.0  106 CD31 cells/kg)
were administered on day 34 6 6 after transplant. Greater than
95% of anti-host cytotoxic T lymphocyte precursors (CTLp)
were depleted from DLIs. All stem cell grafts underwent in vitro
immunomagnetic T cell depletion using CD341 positive cell se-
lection (Miltenyi). The myeloablative regimen consisted of TBI
(1200 cGy), thiotepa (5 mg/kg) and fludarabine (40 mg/m2/day
for 5 days) followed by infusion of CD3 depleted hematopoietic
stem cell grafts. No GVHD prophylaxis was administered. All pa-
tients showed complete donor chimerism and durable hemato-
logic engraftment. No patient developed acute GVHD (grade
II-IV). Eight patients died: 4 of relapsed leukemia (3 AML; 1
ALL) and 4 of infections, all after day1300. In the first 7 patients
who received 1.3  105 or less CD31 cells/kg, 11 infectious ep-
isodes (4 lethal) occurred in these 7 pts (100% of pts). In sharp
contrast, only 5 infectious episodes (none lethal) were observed
in 3 (27%) of the following 11 patients receiving DLI with the
highest doses of CD31 cells (3.2  105 to 5.0  106 CD31
cells/kg) (p \0.05). Chronic GVHD developed in 5 patients,
mostly in those receiving higher T cell doses, and responded rap-
idly to steroid-based immunesuppression. The overall survival is
67% at 2 years (median follow-up: 10.5 mo). Our results indicate
that the post-transplant infusion of an ATIR-PDT treated DLI is
feasible, does not induce acute GVHD, and suggests a clinical
benefit for patients receiving the highest DLI doses to accelerate
T cell reconstitution.46
RAPID RECOVERY OF ABSOLUTE LYMPHOCYTE COUNTS (ALC) IS PRE-
DICTIVE OF FAVORABLE OUTCOMES FOLLOWING UMBILICAL CORD
BLOOD (UCB) TRANSPLANTATION: IMPACT OF THE USE OF TWO UCB
UNITS
Verneris, M.R., Janardan, S., Isaksson, R., Brunstein, C.G.,
Weisdorf, D.J., Miller, J.S., Wagner, J.E. University of Minnesota,
Minneapolis, Mn
After UCB transplantation, neutrophil recovery is markedly
slower than other stem cell sources. The kinetics of lymphocyte re-
covery and their significance has not been extensively evaluated.
We analyzed the maximumweekly ALC based on total white count
and automated differential. To assess the impact of ALC on
transplant outcomes, we analyzed 80 consecutive AML patients
transplanted with UCB after a myeloablative conditioning from
2001–6. Six patients with graft failure or early death were excluded,
resulting in 74 (92.5%) evaluable patients. The median age was
21.4 yrs (range 0.5–43.9). The majority of patients (85.1%) re-
ceived cyclophosphamide (60mg/kg x 2), fludarabine (75mg/m2)
